Search Clinical Trials 2018-08-12T02:31:07+00:00

CAR-T study search 19 Feb 2018

RankNCT NumberTitleRecruitmentStudy ResultsConditionsInterventionsSponsor/CollaboratorsPhasesEnrollmentURL
1NCT03423992Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant GliomasRecruitingNo Results AvailableGlioma|Malignant Glioma of Brain|Recurrence TumorBiological: chimeric antigen receptor T cellsXuanwu Hospital, Beijing|Beijing Mario Biotech Company|Hebei Senlang BIotech CompanyPhase 150https://ClinicalTrials.gov/show/NCT03423992
2NCT03241940CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic LeukemiaRecruitingNo Results AvailableB Acute Lymphoblastic Leukemia|CD19 Positive|Minimal Residual Disease|Philadelphia Chromosome Positive|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic LeukemiaBiological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Other: Questionnaire AdministrationStanford University|National Cancer Institute (NCI)Phase 147https://ClinicalTrials.gov/show/NCT03241940
3NCT03434769AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaNot yet recruitingNo Results AvailableNon-Hodgkin LymphomaDrug: Cyclophosphamide|Drug: Fludarabine|Biological: CAR-T CellsCase Comprehensive Cancer CenterPhase 118https://ClinicalTrials.gov/show/NCT03434769
4NCT03233854CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic LeukemiaRecruitingNo Results AvailableB Acute Lymphoblastic Leukemia|CD19 Positive|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly|Minimal Residual Disease|Philadelphia Chromosome Positive|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell LymphomaBiological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Other: Questionnaire AdministrationCrystal Mackall, MD|Stanford UniversityPhase 157https://ClinicalTrials.gov/show/NCT03233854
5NCT03118180CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell LymphomaRecruitingNo Results AvailableLymphomaBiological: CD19 targeted chimeric antigen receptor T cellsZhejiang University|Innovative Cellular Therapeutics Co., Ltd.Phase 1|Phase 250https://ClinicalTrials.gov/show/NCT03118180
6NCT02992834Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell LymphomaNot yet recruitingNo Results AvailableLymphoma, B CellBiological: IL-2 pre-treated CD19 cells|Biological: IL-7/IL-15 pre-treated CD19 cellsjiangjingting|The First People's Hospital of ChangzhouPhase 410https://ClinicalTrials.gov/show/NCT02992834
7NCT02349698A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and LymphomaRecruitingNo Results AvailableLeukemia|LymphomaBiological: Chimeric Antigen Receptor Modified T cells Targeting CD19Southwest Hospital, ChinaPhase 1|Phase 245https://ClinicalTrials.gov/show/NCT02349698
8NCT02442297T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With GlioblastomaRecruitingNo Results AvailableGlioblastomaBiological: HER2-specific T cellsBaylor College of Medicine|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of MedicinePhase 114https://ClinicalTrials.gov/show/NCT02442297
9NCT02659943T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell MalignanciesRecruitingNo Results AvailableLymphoma, B-Cell|Lymphoma, Non-hodgkinsBiological: Anti-CD19-CAR T cells|Drug: Cyclophosphamide|Drug: FludarabineNational Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Phase 164https://ClinicalTrials.gov/show/NCT02659943
10NCT02959151A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver MalignancyRecruitingNo Results AvailableCarcinoma, Hepatocellular|Pancreatic Cancer Metastatic|Colorectal Cancer MetastaticDrug: CAR-T cellShanghai GeneChem Co., Ltd.|Shanghai Cancer Hospital, ChinaPhase 1|Phase 220https://ClinicalTrials.gov/show/NCT02959151
11NCT03086954Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive LymphomaNot yet recruitingNo Results AvailableLymphomaBiological: The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)Sinobioway Cell Therapy Co., Ltd.|Jiangsu Cancer Institute & HospitalPhase 124https://ClinicalTrials.gov/show/NCT03086954
12NCT03267173Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.RecruitingNo Results AvailablePancreatic Cancer|CARDrug: Chimeric antigen receptor T cellFirst Affiliated Hospital of Harbin Medical University|Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdEarly Phase 110https://ClinicalTrials.gov/show/NCT03267173
13NCT02742727CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and LymphomaRecruitingNo Results AvailableAcute Myeloid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|T-cell Prolymphocytic Leukemia|T-cell Large Granular Lymphocytic Leukemia|Peripheral T-cell Lymphoma, NOS|Angioimmunoblastic T-cell Lymphoma|Extranodal NK/T-cell Lymphoma, Nasal Type|Enteropathy-type Intestinal T-cell Lymphoma|Hepatosplenic T-cell LymphomaBiological: anti-CD7 CAR-pNK cellsPersonGen BioTherapeutics (Suzhou) Co., Ltd.|The First People's Hospital of Hefei|Hefei Binhu HospitalPhase 1|Phase 210https://ClinicalTrials.gov/show/NCT02742727
14NCT03291444CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory LeukemiaRecruitingNo Results AvailableLeukemia, Acute Lymphocytic (ALL)|Leukemia, Acute Myelogenous (AML)|Myelodysplastic SyndromesBiological: Chimeric antigen receptor T cells|Biological: Eps8 peptide specific dendritic cellZhujiang Hospital|Shenzhen Geno-Immune Medical Institute|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPhase 130https://ClinicalTrials.gov/show/NCT03291444
15NCT03327285C-CAR011 Treatment in Subjects With ALL After HSCTNot yet recruitingNo Results AvailableAcute Lymphoblastic Leukemia(ALL)Biological: C-CAR011Peking University People's Hospital|Cellular Biomedicine Group Ltd.40https://ClinicalTrials.gov/show/NCT03327285
16NCT01087294Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell TransplantationRecruitingNo Results AvailableLeukemia, B-cell|Lymphoma, Hodgkins|Lymphoma, Non-hodgkins|Lymphoma, B-CellProcedure: Allogeneic stem cell transplant|Biological: Anti-CD19-chimeric-antigen-receptor- transduced T cellNational Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Phase 1150https://ClinicalTrials.gov/show/NCT01087294
17NCT02813837Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic MalignanciesRecruitingNo Results AvailableLeukemia, B-Cell|Lymphoma, B-CellBiological: CD19CARTInnovative Cellular Therapeutics Co., Ltd.30https://ClinicalTrials.gov/show/NCT02813837
18NCT02259556CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive LymphomasRecruitingNo Results AvailableHodgkin's Lymphoma|Non-Hodgkin's LymphomaBiological: CART30Chinese PLA General HospitalPhase 1|Phase 230https://ClinicalTrials.gov/show/NCT02259556
19NCT02965092CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell MalignanciesRecruitingNo Results AvailableAcute Lymphoblastic Leukemia|B Cell LymphomaGenetic: Second generation CAR-T cellsWuhan Sian Medical Technology Co., Ltd|Wuhan Union Hospital, China|Jingzhou Central Hospital|Xiangyang Central Hospital|People's Hospital Of YichangPhase 150https://ClinicalTrials.gov/show/NCT02965092
20NCT03076437Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell MalignanciesRecruitingNo Results AvailableAcute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|LymphomaCombination Product: Drugs and Anti-CD19-CAR transduced T cellsShenzhen Institute for Innovation and Translational Medicine|Dongguan People's HospitalPhase 1|Phase 236https://ClinicalTrials.gov/show/NCT03076437
21NCT02209376Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ GlioblastomaActive, not recruitingNo Results AvailablePatients With Residual or Reccurent EGFRvIII+ GliomaBiological: CART-EGFRvIII T cellsUniversity of Pennsylvania|University of California, San Francisco12https://ClinicalTrials.gov/show/NCT02209376
22NCT02203825Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-LigandsActive, not recruitingNo Results AvailableAcute Myeloid Leukemia|Myelodysplastic Syndrome|Multiple MyelomaBiological: CM-CS1 T-cell infusionCelyad (formerly named Cardio3 BioSciences)|Dana-Farber Cancer Institute|National Heart, Lung, and Blood Institute (NHLBI)Phase 112https://ClinicalTrials.gov/show/NCT02203825
23NCT02905188Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)Not yet recruitingNo Results AvailableHepatocellular CarcinomaGenetic: GLYCAR T cells|Drug: Cytoxan|Drug: FludarabineBaylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital SystemPhase 114https://ClinicalTrials.gov/show/NCT02905188
24NCT02932956Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)Not yet recruitingNo Results AvailableSolid TumorsGenetic: GAP T cells|Drug: Cytoxan|Drug: FludaraBaylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's HospitalPhase 114https://ClinicalTrials.gov/show/NCT02932956
25NCT02186860Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic LeukemiaRecruitingNo Results AvailableAcute Lymphoblastic LeukemiaBiological: Third generation CAR-T cellsAffiliated Hospital to Academy of Military Medical Sciences|Peking UniversityPhase 15https://ClinicalTrials.gov/show/NCT02186860
26NCT02456350Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell MalignanciesRecruitingNo Results AvailableChronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia|LymphomaDrug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-CD19-CAR transduced T cellsShenzhen Second People's Hospital|Shenzhen Institute for Innovation and Translational MedicinePhase 136https://ClinicalTrials.gov/show/NCT02456350
27NCT03049449T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing LymphomasRecruitingNo Results AvailableLymphoma, Large-Cell, Anaplasitc|Hodgkin Disease|Lymphoma, Hodgkins|Enteropathy-Associated T-Cell Lymphoma|Lymphoma, Extranodal NK-T-CellBiological: Anti-CD30-CAR T cells|Drug: Cyclophosphamide|Drug: FludarabineNational Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Phase 176https://ClinicalTrials.gov/show/NCT03049449
28NCT03302403Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsNot yet recruitingNo Results AvailableB Cell Lymphoma|B Cell Leukemia|Myeloma|Hepatocellular Carcinoma|Pancreatic Carcinoma|Adenocarcinoma of Esophagogastric JunctionGenetic: CAR-CD19 T cell|Genetic: CAR-BCMA T cell|Genetic: CAR-GPC3 T cell|Genetic: CAR-CLD18 T cell|Drug: Fludarabine|Drug: CyclophosphamideKang YU|Carsgen Therapeutics, Ltd.|First Affiliated Hospital of Wenzhou Medical Univeristy48https://ClinicalTrials.gov/show/NCT03302403
29NCT018226523rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAINActive, not recruitingNo Results AvailableNeuroblastomaGenetic: iC9-GD2 T Cell Lymphocytes-frozen cells|Genetic: iC9-GD2 T Cell Lymphocytes-fresh cells|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: pembrolizumabBaylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Solving Kids’ Cancer|The EVAN Foundation|National Cancer Institute (NCI)|Kids' Cancer Research FoundationPhase 111https://ClinicalTrials.gov/show/NCT01822652
30NCT03144583Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to TherapyRecruitingNo Results AvailableLeukemia|LymphomaBiological: Adult differentiated autologous T-cellsSara V. Latorre|Instituto de Salud Carlos III|Institut d'Investigacions Biomèdiques August Pi i SunyerPhase 139https://ClinicalTrials.gov/show/NCT03144583
31NCT02839954CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid TumorRecruitingNo Results AvailableHepatocellular Carcinoma|Non-small Cell Lung Cancer|Pancreatic Carcinoma|Triple-Negative Invasive Breast Carcinoma|Malignant Glioma of Brain|Colorectal Carcinoma|Gastric CarcinomaBiological: anti-MUC1 CAR-pNK cellsPersonGen BioTherapeutics (Suzhou) Co., Ltd.|The First People's Hospital of Hefei|Hefei Binhu HospitalPhase 1|Phase 210https://ClinicalTrials.gov/show/NCT02839954
32NCT03277729A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasRecruitingNo Results AvailableCD20 Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Transformed Indolent Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell LymphomaBiological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: LeukapheresisFred Hutchinson Cancer Research Center|National Cancer Institute (NCI)Phase 1|Phase 230https://ClinicalTrials.gov/show/NCT03277729
33NCT02765243Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent NeuroblastomaRecruitingNo Results AvailableNeuroblastoma|Effects of ImmunotherapyBiological: Anti-GD2 CARTZhujiang HospitalPhase 230https://ClinicalTrials.gov/show/NCT02765243
34NCT03203369Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCNRecruitingNo Results AvailableBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Biological: UCART123Cellectis S.A.Phase 172https://ClinicalTrials.gov/show/NCT03203369
35NCT00902044Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced SarcomaRecruitingNo Results AvailableSarcomaGenetic: Autologous HER2-specific T cells|Drug: Fludarabine|Drug: CyclophosphamideBaylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of MedicinePhase 136https://ClinicalTrials.gov/show/NCT00902044
36NCT02349724A Clinical Research of CAR T Cells Targeting CEA Positive CancerRecruitingNo Results AvailableLung Cancer|Colorectal Cancer|Gastric Cancer|Breast Cancer|Pancreatic CancerBiological: Anti-CEA-CAR TSouthwest Hospital, ChinaPhase 175https://ClinicalTrials.gov/show/NCT02349724
37NCT02830724Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingNo Results AvailablePancreatic Cancer|Renal Cell Cancer|Breast Cancer|Melanoma|Ovarian CancerDrug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin|Biological: Anti-hCD70 CAR PBLNational Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Phase 1|Phase 2113https://ClinicalTrials.gov/show/NCT02830724
38NCT02772198T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell MalignanciesRecruitingNo Results AvailableAcute Lymphoblastic Leukemia, B-precursor|Non-Hodgkin Lymphoma, B-cellBiological: CD19 CAR T cellsSheba Medical CenterPhase 1|Phase 240https://ClinicalTrials.gov/show/NCT02772198
39NCT02650999Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ LymphomasRecruitingNo Results AvailableCD19+ Diffuse Large B-cell Lymphomas|Follicular Lymphomas|Mantle Cell LymphomasDrug: PembrolizumabAbramson Cancer Center of the University of PennsylvaniaPhase 1|Phase 212https://ClinicalTrials.gov/show/NCT02650999
40NCT03126864Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid LeukemiaRecruitingNo Results AvailableHematopoietic/Lymphoid Cancer|Acute Myeloid LeukemiaProcedure: Leukapheresis|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: CD33-CAR-T Cell InfusionM.D. Anderson Cancer Center|Intrexon Corporation|ZiopharmPhase 139https://ClinicalTrials.gov/show/NCT03126864
41NCT02640209Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)Active, not recruitingNo Results AvailableLYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)Biological: CART 19University of Pennsylvania20https://ClinicalTrials.gov/show/NCT02640209
42NCT03018093A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALLRecruitingNo Results AvailableRelapsed or Refractory Acute Lymphoblastic LeukemiaBiological: C-CAR-011Cellular Biomedicine Group Ltd.|Chinese PLA General HospitalPhase 120https://ClinicalTrials.gov/show/NCT03018093
43NCT02919046Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in ChildrenRecruitingNo Results AvailableRelapsed or Refractory NeuroblastomaBiological: GD2-targeted CAR-T cellsSinobioway Cell Therapy Co., Ltd.|Nanjing Children's Hospital|Children's Hospital of Fudan University22https://ClinicalTrials.gov/show/NCT02919046
44NCT03355859Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingNo Results AvailableNon Hodgkin LymphomaBiological: JWCAR029Zhao Weili|MingJu Therapeutics (Shanghai) Co., Ltd|Ruijin HospitalPhase 110https://ClinicalTrials.gov/show/NCT03355859
45NCT03344367Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingNo Results AvailableNon Hodgkin LymphomaBiological: JWCAR029Peking University|MingJu Therapeutics (Shanghai) Co., LtdPhase 120https://ClinicalTrials.gov/show/NCT03344367
46NCT02944162CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AMLRecruitingNo Results AvailableAcute Myelogenous Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia With Maturation|Acute Myeloid Leukemia Without Maturation|ANLLBiological: anti-CD33 CAR-NK cellsPersonGen BioTherapeutics (Suzhou) Co., Ltd.|The First People's Hospital of Hefei|Hefei Binhu HospitalPhase 1|Phase 210https://ClinicalTrials.gov/show/NCT02944162
47NCT01840566High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin LymphomaActive, not recruitingNo Results AvailableNon-Hodgkin's LymphomaDrug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Biological: Pegfilgrastim|Biological: 19-28z T CELLS|Procedure: Autologous Stem Cell TransplantationMemorial Sloan Kettering Cancer CenterPhase 117https://ClinicalTrials.gov/show/NCT01840566
48NCT01747486CD19 Redirected Autologous T CellsActive, not recruitingNo Results AvailableAdult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLLBiological: CART-19University of PennsylvaniaPhase 261https://ClinicalTrials.gov/show/NCT01747486
49NCT03154775Study of Safety and Efficacy of C-CAR011 in B-NHL PatientsRecruitingNo Results AvailableRefractory or Relapsed Non-Hodgkin LymphomaBiological: C-CAR011Cellular Biomedicine Group Ltd.|Shanghai Tongji Hospital, Tongji University School of MedicinePhase 115https://ClinicalTrials.gov/show/NCT03154775
50NCT02915445EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast CancerRecruitingNo Results AvailableMalignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M)|Breast Cancer RecurrentBiological: CAR-T cells recognizing EpCAMSichuan UniversityPhase 130https://ClinicalTrials.gov/show/NCT02915445
51NCT03373097Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory NeuroblastomaRecruitingNo Results AvailableNeuroblastoma|Neuroblastoma RecurrentBiological: GD2-CART01Bambino Gesù Hospital and Research InstitutePhase 1|Phase 242https://ClinicalTrials.gov/show/NCT03373097
52NCT02664363EGFRvIII CAR T Cells for Newly-Diagnosed GBMRecruitingNo Results AvailableGlioblastoma|GliosarcomaBiological: EGFRvIII CAR T cellsGary Archer Ph.D.|Duke UniversityPhase 148https://ClinicalTrials.gov/show/NCT02664363
53NCT03373071Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHLRecruitingNo Results AvailableCD19-ALL|CD19-LNHBiological: CD19-CAR T cellBambino Gesù Hospital and Research InstitutePhase 1|Phase 232https://ClinicalTrials.gov/show/NCT03373071
54NCT03344705Safety and Efficacy Evaluation of IM19 CellsRecruitingNo Results AvailableHematological MalignanciesBiological: IM19 CAR-T|Drug: Fludarabine|Drug: CyclophosphamideBeijing Immunochina Medical Science & Technology Co., Ltd.Phase 120https://ClinicalTrials.gov/show/NCT03344705
55NCT02892695PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and LymphomaRecruitingNo Results AvailableAcute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|B-cell Prolymphocytic Leukemia|Diffuse Large Cell LymphomaBiological: anti-CD19 CAR-NK cellsPersonGen BioTherapeutics (Suzhou) Co., Ltd.|The First People's Hospital of Hefei|Hefei Binhu HospitalPhase 1|Phase 210https://ClinicalTrials.gov/show/NCT02892695
56NCT02706392Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ MalignanciesRecruitingNo Results AvailableEstrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Non-Small Cell Lung Cancer AJCC v7|Triple-Negative Breast CarcinomaOther: Laboratory Biomarker Analysis|Biological: ROR1 CAR-specific Autologous T-LymphocytesFred Hutchinson Cancer Research Center|National Cancer Institute (NCI)Phase 160https://ClinicalTrials.gov/show/NCT02706392
57NCT01683279A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic LeukemiaActive, not recruitingNo Results AvailableB Cell LeukemiaBiological: Autologous CD19 CAR+ EGFTt + T cellsSeattle Children's HospitalPhase 118https://ClinicalTrials.gov/show/NCT01683279
58NCT03114670Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCTRecruitingNo Results AvailableAdult Acute Myeloid LeukemiaBiological: CD123CAR-41BB-CD3zeta-EGFRt-expressing T cellsAffiliated Hospital to Academy of Military Medical SciencesPhase 120https://ClinicalTrials.gov/show/NCT03114670
59NCT03240328The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune FunctionNot yet recruitingNo Results AvailableHIV/AIDSBiological: CAR-T cellsGuangzhou 8th People's Hospital|Sun Yat-sen UniversityPhase 140https://ClinicalTrials.gov/show/NCT03240328
60NCT03262298Anti-CD22 CAR-T Cell Therapy Targeting B Cell MalignanciesActive, not recruitingNo Results AvailableLeukemia|LymphomaBiological: Anti-CD22-CAR-transduced T cellsAffiliated Hospital to Academy of Military Medical SciencesPhase 1|Phase 220https://ClinicalTrials.gov/show/NCT03262298
61NCT03275493Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic LeukemiaNot yet recruitingNo Results AvailableAcute Lymphoblastic Leukemia|CD19 Positive|Relapse|RefractoryBiological: Humanized CD19 CAR-T cells|Biological: Humanized CD19 CAR-T cells with CRS suppression technologyShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|The First Affiliated Hospital of Soochow UniversityPhase 1|Phase 240https://ClinicalTrials.gov/show/NCT03275493
62NCT03298828CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and LymphomaNot yet recruitingNo Results AvailableAcute Lymphoblastic Leukemia|Burkitt LymphomaBiological: CD19 CAR and PD-1 knock out engineered T-cells|Biological: CD19 CAR T-cellsThird Military Medical UniversityPhase 130https://ClinicalTrials.gov/show/NCT03298828
63NCT02761915A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART)RecruitingNo Results AvailableRelapsed or Refractory NeuroblastomaGenetic: 1RG-CART/m^2 (Dose Level 1)|Genetic: 1RG-CART/m^2 (Dose Level 2)|Genetic: 1RG-CART/m^2 (Dose Level 3)|Genetic: 1RG-CART/m^2 (Dose Level 4)|Drug: Cyclophosphamide|Drug: Fludarabine|Genetic: 1RG-CART/m^2 (Dose Level 5)Cancer Research UKPhase 127https://ClinicalTrials.gov/show/NCT02761915
64NCT02844062Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma MultiformeRecruitingNo Results AvailableGlioblastoma MultiformeBiological: anti-EGFRvIII CAR T cells|Drug: cyclophosphamide|Drug: FludarabineBeijing Sanbo Brain Hospital|Marino Biotechnology Co., Ltd.Phase 120https://ClinicalTrials.gov/show/NCT02844062
65NCT03030001PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced MalignanciesRecruitingNo Results AvailableSolid Tumor, Adult|Advanced CancerBiological: PD-1 antibody expressing mesothelin specific CAR-T cellsNingbo Cancer HospitalPhase 1|Phase 240https://ClinicalTrials.gov/show/NCT03030001
66NCT02799680Allogeneic CART-33 for Relapsed/Refractory CD33+ AMLRecruitingNo Results AvailableRelapsed and/or Refractory CD33+ AMLBiological: allogeneic CART-33The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Chinese PLA General HospitalPhase 112https://ClinicalTrials.gov/show/NCT02799680
67NCT02842138Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell LymphomaRecruitingNo Results AvailableB-cell LymphomaBiological: autologous anti-CD19 CAR T cellsPeking University|Marino Biotechnology Co., Ltd.Phase 125https://ClinicalTrials.gov/show/NCT02842138
68NCT02799550Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALLRecruitingNo Results AvailableLeukemiaBiological: allogeneic CART-19The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Chinese PLA General HospitalPhase 110https://ClinicalTrials.gov/show/NCT02799550
69NCT02930993Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant TumorsRecruitingNo Results AvailableMesothelin Positive TumorsBiological: anti-mesothelin CAR T cellsChina Meitan General Hospital|Marino Biotechnology Co., Ltd.Phase 120https://ClinicalTrials.gov/show/NCT02930993
70NCT02935543CART19 in Patient With ALLRecruitingNo Results AvailableLeukemia, Acute LymphoblasticBiological: CART 19University of PennsylvaniaPhase 224https://ClinicalTrials.gov/show/NCT02935543
71NCT02650414CD22 Redirected Autologous T Cells for ALLRecruitingNo Results AvailableB Cell Leukemias|B Cell LymphomasBiological: CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BBUniversity of Pennsylvania|Children's Hospital of PhiladelphiaPhase 115https://ClinicalTrials.gov/show/NCT02650414
72NCT03190278Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid LeukemiaRecruitingNo Results AvailableAcute Myeloid LeukemiaBiological: UCART123Cellectis S.A.Phase 1156https://ClinicalTrials.gov/show/NCT03190278
73NCT02537977CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell MalignancyRecruitingNo Results AvailableLeukemia|LymphomaBiological: CD19-directed CAR-T cellsShanghai Tongji Hospital, Tongji University School of MedicinePhase 1|Phase 240https://ClinicalTrials.gov/show/NCT02537977
74NCT03103971huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaRecruitingNo Results AvailableAdult B Acute Lymphoblastic Leukemia|BCL2 Gene Rearrangement|BCL6 Gene Rearrangement|CD19 Positive|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|MYC Gene Rearrangement|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Adult Acute Lymphoblastic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Transformed Recurrent Non-Hodgkin LymphomaBiological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis|Other: Pharmacological StudyFred Hutchinson Cancer Research Center|National Cancer Institute (NCI)Phase 166https://ClinicalTrials.gov/show/NCT03103971
75NCT03283631Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBMNot yet recruitingNo Results AvailableRecurrent Glioblastoma Multiforme|Recurrent Brain Tumor, AdultBiological: EGFRvIII-CARsGary Archer Ph.D.|National Cancer Institute (NCI)|Duke Cancer Institute|Duke UniversityPhase 124https://ClinicalTrials.gov/show/NCT03283631
76NCT02431988Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic TransplantationRecruitingNo Results AvailableDiffuse Large B-Cell LymphomaProcedure: Leukapheresis|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CAR19 T-CellsUniversity College, LondonPhase 112https://ClinicalTrials.gov/show/NCT02431988
77NCT02744287Prostate Stem Cell Antigen (PSCA)-Specific CAR T Cells In Subjects With Non-Resectable Pancreatic CancerRecruitingNo Results AvailableNon-Resectable Pancreatic CancerBiological: BPX-601|Drug: RimiducidBellicum PharmaceuticalsPhase 130https://ClinicalTrials.gov/show/NCT02744287
78NCT03366350Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell MalignanciesRecruitingNo Results AvailableAcute Lymphoblastic Leukemia|B Cell LymphomaGenetic: Second generation CAR-T cells|Procedure: Hematological stem cell transplantationWuhan Sian Medical Technology Co., Ltd|Wuhan Union Hospital, China|Jingzhou Central Hospital|Xiangyang Central Hospital|People's Hospital Of YichangPhase 1|Phase 230https://ClinicalTrials.gov/show/NCT03366350
79NCT02976857A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL SubjectsRecruitingNo Results AvailableRefractory Diffuse Large B-Cell LymphomaBiological: C-CAR-011Cellular Biomedicine Group Ltd.|The First Affiliated Hospital with Nanjing Medical UniversityPhase 115https://ClinicalTrials.gov/show/NCT02976857
80NCT03294954GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With NeuroblastomaNot yet recruitingNo Results AvailableNeuroblastomaGenetic: GINAKIT Cells|Drug: Cyclophosphamide|Drug: FludarabineBaylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's HospitalPhase 124https://ClinicalTrials.gov/show/NCT03294954
81NCT02706405JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaRecruitingNo Results AvailableBCL2 Gene Rearrangement|BCL6 Gene Rearrangement|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|MYC Gene Rearrangement|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mediastinal (Thymic) Large B-Cell Cell LymphomaBiological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Drug: Cyclophosphamide|Biological: Durvalumab|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Other: Pharmacological StudyFred Hutchinson Cancer Research Center|AstraZeneca|Juno Therapeutics, Inc.|MedImmune LLC|National Cancer Institute (NCI)Phase 142https://ClinicalTrials.gov/show/NCT02706405
82NCT02617134CAR-T Cell Immunotherapy in MUC1 Positive Solid TumorRecruitingNo Results AvailableMalignant Glioma of Brain|Colorectal Carcinoma|Gastric CarcinomaBiological: anti-MUC1 CAR-T cellsPersonGen BioTherapeutics (Suzhou) Co., Ltd.|The First People's Hospital of Hefei|Hefei Binhu HospitalPhase 1|Phase 220https://ClinicalTrials.gov/show/NCT02617134
83NCT02311621Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01RecruitingNo Results AvailableNeuroblastoma|GanglioneuroblastomaBiological: Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)|Biological: Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)Seattle Children's Hospital|EVAN Foundation|Ben Towne Center for Childhood Cancer ResearchPhase 140https://ClinicalTrials.gov/show/NCT02311621
84NCT03030976A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)RecruitingNo Results AvailableSystemic Lupus Erythematosus (SLE)Drug: cyclophosphamide|Drug: anti-CD19-CAR-T cellsShanghai GeneChem Co., Ltd.|RenJi HospitalPhase 15https://ClinicalTrials.gov/show/NCT03030976
85NCT02851589Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaRecruitingNo Results AvailableAcute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|B-cell Prolymphocytic Leukemia|Diffuse Large Cell LymphomaBiological: PCAR-019 (anti-CD19 CAR-T cells)PersonGen BioTherapeutics (Suzhou) Co., Ltd.|Anhui Provincial HospitalPhase 1|Phase 210https://ClinicalTrials.gov/show/NCT02851589
86NCT02819583CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaRecruitingNo Results AvailableAcute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|B-cell Prolymphocytic Leukemia|Diffuse Large Cell LymphomaBiological: PCAR-019 (anti-CD19 CAR-T cells)PersonGen BioTherapeutics (Suzhou) Co., Ltd.|The First People's Hospital of Hefei|Hefei Binhu Hospital|Anhui Provincial HospitalPhase 1|Phase 210https://ClinicalTrials.gov/show/NCT02819583
87NCT02690545Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHLRecruitingNo Results AvailableLymphoma|Lymphoma, Non-Hodgkin|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases|Lymphoproliferative Disorders|Neoplasms|Neoplasms by Histologic TypeBiological: ATLCAR.CD30 cellsUNC Lineberger Comprehensive Cancer CenterPhase 1|Phase 231https://ClinicalTrials.gov/show/NCT02690545
88NCT02672501A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell LeukemiaRecruitingNo Results AvailableLeukemia, B-CellDrug: anti-CD19-CAR-T cellsShanghai GeneChem Co., Ltd.Phase 1|Phase 230https://ClinicalTrials.gov/show/NCT02672501
89NCT02050347Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)RecruitingNo Results AvailableNon-Hodgkin's Lymphoma|B-Cell ALL|B-Cell CLLGenetic: CD19.CAR-CD28Z T Cells - dose escalation 2|Genetic: CD19.CAR-CD28Z T Cells - dose escalation 1Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital SystemPhase 140https://ClinicalTrials.gov/show/NCT02050347
90NCT02663297Administration of T Lymphocytes for Prevention of Relapse of LymphomasRecruitingNo Results AvailableHodgkin Disease|Lymphoma|Lymphoma, Non-Hodgkin|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases|Lymphoproliferative Disorders|Neoplasms|Neoplasms by Histologic TypeDrug: ATLCAR.CD30 cellsUNC Lineberger Comprehensive Cancer Center|National Heart, Lung, and Blood Institute (NHLBI)Phase 118https://ClinicalTrials.gov/show/NCT02663297
91NCT01953900iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma/VEGASActive, not recruitingNo Results AvailableSarcomasGenetic: GD2 T cells|Biological: VZV vaccineBaylor College of Medicine|National Cancer Institute (NCI)|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System|Texas Children's HospitalPhase 126https://ClinicalTrials.gov/show/NCT01953900
92NCT02933775CD19-redirected Autologous Cells (CAR-CD19 T Cells)Not yet recruitingNo Results AvailableCD19 Positive Malignant B-cell Leukemia and LymphomaGenetic: CAR-CD19 T cells|Drug: Fludarabine|Drug: CyclophosphamideRenJi Hospital|Carsgen Therapeutics, Ltd.Phase 145https://ClinicalTrials.gov/show/NCT02933775
93NCT03281551Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell LymphomaRecruitingNo Results AvailableB-cell Acute Lymphoblastic Leukemia|B-cell LymphomaDrug: PZ01 CAR-T cellsPinze Lifetechnology Co. Ltd.|Chinese Academy of Sciences|Navy General Hospital, BeijingPhase 150https://ClinicalTrials.gov/show/NCT03281551
94NCT03146234CAR-GPC3 T Cells in Patients With Refractory Hepatocellular CarcinomaRecruitingNo Results AvailableHepatocellular CarcinomaGenetic: CAR-GPC3 T cellsRenJi Hospital|Carsgen Therapeutics, Ltd.20https://ClinicalTrials.gov/show/NCT03146234
95NCT03159819Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic AdenocarcinomaNot yet recruitingNo Results AvailableAdvanced Gastric Adenocarcinoma|Pancreatic AdenocarcinomaGenetic: CAR-CLD18 T CellsChanghai Hospital|Carsgen Therapeutics, Ltd.24https://ClinicalTrials.gov/show/NCT03159819
96NCT03380039Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple MyelomaRecruitingNo Results AvailableRefractory or Relapsed Multiple MyelomaGenetic: CAR-BCMA T cells|Drug: Fludarabine|Drug: CyclophosphamideXinhua Hospital, Shanghai Jiao Tong University School of Medicine|Carsgen Therapeutics, Ltd.12https://ClinicalTrials.gov/show/NCT03380039
97NCT02081937CART-19 Immunotherapy in Mantle Cell LymphomaRecruitingNo Results AvailableHematopoietic/Lymphoid Cancer|Non-hodgkin Lymphoma,B Cell|Mantle Cell LymphomaBiological: anti-CD19-CAR vector-transduced T cellsChinese PLA General HospitalPhase 1|Phase 22https://ClinicalTrials.gov/show/NCT02081937
98NCT03093168BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple MyelomaRecruitingNo Results AvailableMultiple MyelomaBiological: Anti-BCMA CAR-T cells|Drug: Fludarabine|Drug: CyclophosphamideThe Second Affiliated Hospital of Henan University of Traditional Chinese Medicine|Xinqiao Hospital of ChongqingPhase 110https://ClinicalTrials.gov/show/NCT03093168
99NCT03070327BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple MyelomaRecruitingNo Results AvailableMultiple MyelomaBiological: EGFRt/BCMA-41BBz CAR T cell|Drug: Cyclophosphamide|Drug: Lenalidomide.Memorial Sloan Kettering Cancer Center|Juno Therapeutics, Inc.Phase 136https://ClinicalTrials.gov/show/NCT03070327
100NCT03244306A Phase 1 Study of CD22 CAR T-Cell Immunotherapy for CD22+ LeukemiaRecruitingNo Results AvailableLeukemiaBiological: Patient-derived CD22-specific CAR T-cells also expressing an EGFRtSeattle Children's HospitalPhase 133https://ClinicalTrials.gov/show/NCT03244306
101NCT02529813CD19+ CAR T Cells for Lymphoid MalignanciesRecruitingNo Results AvailableLeukemia|LymphomaDrug: Fludarabine monophosphate|Drug: Cyclophosphamide|Procedure: T Cell InfusionM.D. Anderson Cancer Center|Ziopharm|Intrexon CorporationPhase 130https://ClinicalTrials.gov/show/NCT02529813
102NCT03430011Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNo Results AvailableMultiple MyelomaBiological: JCARH125Juno Therapeutics, Inc.Phase 1|Phase 2118https://ClinicalTrials.gov/show/NCT03430011
103NCT01865617Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic LeukemiaRecruitingNo Results AvailableCD19-Positive Neoplastic Cells Present|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic LymphomaBiological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes|Other: Laboratory Biomarker AnalysisFred Hutchinson Cancer Research Center|National Cancer Institute (NCI)Phase 1|Phase 2189https://ClinicalTrials.gov/show/NCT01865617
104NCT02631044Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)RecruitingNo Results AvailableNon-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle-cell Lymphoma|Primary Mediastinal B-cell LymphomaBiological: JCAR017 (lisocabtagene maraleucel) single-dose schedule|Biological: JCAR017 (lisocabtagene maraleucel) 2-dose scheduleJuno Therapeutics, Inc.|CelgenePhase 1274https://ClinicalTrials.gov/show/NCT02631044
105NCT02792114T-Cell Therapy for Advanced Breast CancerRecruitingNo Results AvailableBreast Cancer|Metastatic HER2-negative BreastDrug: Cyclophosphamide|Biological: Mesothelin-targeted T cells|Drug: AP1903Memorial Sloan Kettering Cancer Center|United States Department of DefensePhase 124https://ClinicalTrials.gov/show/NCT02792114
106NCT03186118Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ LeukemiaRecruitingNo Results AvailableCD 19+ Acute LeukemiaBiological: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)Seattle Children's HospitalPhase 130https://ClinicalTrials.gov/show/NCT03186118
107NCT03060356Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)RecruitingNo Results AvailableMalignant Melanoma|Breast CancerBiological: T cells modified with RNA anti -cMET CARUniversity of PennsylvaniaEarly Phase 110https://ClinicalTrials.gov/show/NCT03060356
108NCT02546739Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLLNot yet recruitingNo Results AvailableLeukemia|LymphomaBiological: Anti-CD19-CARBeijing Doing Biomedical Co., Ltd.|First Hospital of Jilin University|Tianjin People's HospitalPhase 1100https://ClinicalTrials.gov/show/NCT02546739
109NCT02656147Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLLNot yet recruitingNo Results AvailableLeukemia|LymphomaBiological: Anti-CD19-CAR γδTBeijing Doing Biomedical Co., Ltd.Phase 148https://ClinicalTrials.gov/show/NCT02656147
110NCT03056339Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid MalignanciesRecruitingNo Results AvailableB-Lymphoid Malignancies|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non-hodgkin LymphomaDrug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells|Drug: AP1903M.D. Anderson Cancer Center|Bellicum PharmaceuticalsPhase 1|Phase 236https://ClinicalTrials.gov/show/NCT03056339
111NCT02729493Study Evaluating the Efficacy and Safety With CAR-T for Liver CancerRecruitingNo Results AvailableLiver NeoplasmsBiological: EPCAM-targeted CAR-T cellsSinobioway Cell Therapy Co., Ltd.25https://ClinicalTrials.gov/show/NCT02729493
112NCT02725125Study Evaluating the Efficacy and Safety With CAR-T for Stomach CancerRecruitingNo Results AvailableStomach NeoplasmsBiological: EPCAM-targeted CAR-T cellsSinobioway Cell Therapy Co., Ltd.19https://ClinicalTrials.gov/show/NCT02725125
113NCT02735291Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte LeukemiaRecruitingNo Results AvailableLeukemiaBiological: CD19-targeted CAR-T cellsSinobioway Cell Therapy Co., Ltd.|The Second Hospital of Anhui Medical University24https://ClinicalTrials.gov/show/NCT02735291
114NCT02893189CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic TransplantationRecruitingNo Results AvailableCD19+ Malignancies: Relapse Post-allogeneic TransplantGenetic: Infusion of modified CAR19 T-cells (4G7-CARD T-cells)University College, LondonPhase 112https://ClinicalTrials.gov/show/NCT02893189
115NCT02728882Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell LymphomaRecruitingNo Results AvailableLymphomaBiological: CD19-targeted CAR-T cellsSinobioway Cell Therapy Co., Ltd.|The First Affiliated Hospital of Anhui Medical University24https://ClinicalTrials.gov/show/NCT02728882
116NCT03081910Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 AntigenRecruitingNo Results AvailableT-cell Acute Lymphoblastic Lymphoma|T-non-Hodgkin Lymphoma|T-cell Acute Lymphoblastic LeukemiaGenetic: CD5.CAR/28zeta CAR T cells|Drug: Fludarabine|Drug: CytoxanBaylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System|Texas Children's HospitalPhase 121https://ClinicalTrials.gov/show/NCT03081910
117NCT03356808Intervention of CAR-T Against Lung CancerRecruitingNo Results AvailableLung CancerBiological: Lung cancer-specific CAR-T cellsShenzhen Geno-Immune Medical InstitutePhase 1|Phase 220https://ClinicalTrials.gov/show/NCT03356808
118NCT03356795Intervention of CAR-T Against Cervical CancerRecruitingNo Results AvailableCervical CancerBiological: Cervical cancer-specific CAR-T cellsShenzhen Geno-Immune Medical InstitutePhase 1|Phase 220https://ClinicalTrials.gov/show/NCT03356795
119NCT03173417Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)RecruitingNo Results AvailableLeukemiaBiological: IM19 CAR-T|Drug: fludarabine and cyclophosphamideBeijing Immunochina Medical Science & Technology Co., Ltd.Phase 1|Phase 2300https://ClinicalTrials.gov/show/NCT03173417
120NCT01109095CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBMActive, not recruitingNo Results AvailableGlioblastoma Multiforme (GBM)Biological: Genetically modified HER.CAR CMV-specific CTLsBaylor College of Medicine|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's HospitalPhase 116https://ClinicalTrials.gov/show/NCT01109095
121NCT03361748Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)RecruitingNo Results AvailableMultiple MyelomaBiological: bb2121CelgenePhase 294https://ClinicalTrials.gov/show/NCT03361748
122NCT03323944CAR T Cell Immunotherapy for Pancreatic CancerActive, not recruitingNo Results AvailablePancreatic Cancer|Cancer of the PancreasBiological: huCART-meso cellsUniversity of PennsylvaniaPhase 118https://ClinicalTrials.gov/show/NCT03323944
123NCT03054298CAR T Cells in Mesothelin Expressing CancersActive, not recruitingNo Results AvailableLung Adenocarcinoma|Ovarian Cancer|Peritoneal Carcinoma|Fallopian Tube Cancer|Mesotheliomas Pleural|Mesothelioma PeritoneumBiological: Hu-CART meso cellsUniversity of PennsylvaniaPhase 130https://ClinicalTrials.gov/show/NCT03054298
124NCT03196830CAR-T for R/R B-NHLRecruitingNo Results AvailableRelapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|CAR - T CD19/CD20/CD22/CD30Biological: CAR-TThe First Affiliated Hospital of Soochow University|Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdPhase 210https://ClinicalTrials.gov/show/NCT03196830
125NCT03207178Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell LymphomaRecruitingNo Results AvailableRecurrent or Refractory B Cell MalignancyBiological: Mixed CD19/CD20 CAR-T TransferShanghai Longyao Biotechnology Inc., Ltd.|Xuzhou Medical University|Shanghai Jiao Tong University School of MedicinePhase 1|Phase 220https://ClinicalTrials.gov/show/NCT03207178
126NCT01316146Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)Active, not recruitingNo Results AvailableNon-Hodgkin's Lymphoma|Hodgkin's LymphomaDrug: CAR.CD30 T cellsUNC Lineberger Comprehensive Cancer Center|The Methodist Hospital System|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine|Baylor College of MedicinePhase 110https://ClinicalTrials.gov/show/NCT01316146
127NCT03222674CAR T in the Treatment of AMLRecruitingNo Results AvailableAcute Myeloid LeukemiaBiological: Muc1/CD33/CD38/CD56/CD117/CD123-specific gene-engineered T cellsShenzhen Geno-Immune Medical InstitutePhase 1|Phase 210https://ClinicalTrials.gov/show/NCT03222674
128NCT01853631Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)RecruitingNo Results AvailableNon-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic LeukemiaBiological: CD19 CAR T Cells|Drug: Fludarabine|Drug: CyclophosphamideBaylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital SystemPhase 164https://ClinicalTrials.gov/show/NCT01853631
129NCT00924326CAR T Cell Receptor Immunotherapy for Patients With B-cell LymphomaActive, not recruitingNo Results AvailablePrimary Mediastinal B-cell Lymphoma|Diffuse, Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma|Mantle CellDrug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-CD19-CAR PBLNational Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Phase 143https://ClinicalTrials.gov/show/NCT00924326
130NCT01454596CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIIIRecruitingNo Results AvailableMalignant Glioma|Glioblastoma|Brain CancerBiological: Anti-EGFRvIII CAR transduced PBL|Drug: Aldesleukin|Drug: Fludarabine|Drug: CyclophosphamideNational Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Phase 1|Phase 2107https://ClinicalTrials.gov/show/NCT01454596
131NCT03090659LCAR-B38M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple MyelomaEnrolling by invitationNo Results AvailableRefractory or Relapsed Multiple MyelomaBiological: LCAR-B38M CAR-T cell injectionNanjing Legend Biotech Co.|Second Affiliated Hospital of Xi'an Jiaotong University|Ruijin Hospital|Jiangsu Provincial People's Hospital|Shanghai Changzheng HospitalPhase 1|Phase 2100https://ClinicalTrials.gov/show/NCT03090659
132NCT03130712A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)RecruitingNo Results AvailableCarcinoma, HepatocellularDrug: GPC3-CART cellsShanghai GeneChem Co., Ltd.|Beijing 302 HospitalPhase 1|Phase 210https://ClinicalTrials.gov/show/NCT03130712
133NCT00881920Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALLRecruitingNo Results AvailableLymphoma|Myeloma|LeukemiaBiological: Kappa CD28 T cellsBaylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of MedicinePhase 154https://ClinicalTrials.gov/show/NCT00881920
134NCT03085173A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic MalignanciesRecruitingNo Results AvailableChronic Lymphocytic Leukemia (CLL)|Relapsed|RefractoryBiological: EGFRt/19-28z/4-1BBL CAR T cellsMemorial Sloan Kettering Cancer Center|Juno Therapeutics, Inc.Phase 130https://ClinicalTrials.gov/show/NCT03085173
135NCT02876978Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell CarcinomaRecruitingNo Results AvailableLung Squamous Cell CarcinomaGenetic: CAR-GPC3 T Cells|Drug: Fludarabine|Drug: CyclophosphamideCarsgen Therapeutics, Ltd.Phase 120https://ClinicalTrials.gov/show/NCT02876978
136NCT02735083A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19Enrolling by invitationNo Results AvailableAdvanced Lymphoid MalignanciesGenetic: UCART19 follow-upInstitut de Recherches Internationales Servier|Servier200https://ClinicalTrials.gov/show/NCT02735083
137NCT03110640Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/LymphomaNot yet recruitingNo Results AvailableB-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Hematopoietic/Lymphoid Cancer|Refractory Chronic Lymphocytic LeukemiaBiological: anti-CD19 CAR-T|Drug: Fludarabine|Drug: CyclophosphamideFirst Affiliated Hospital of Wenzhou Medical UniveristyPhase 120https://ClinicalTrials.gov/show/NCT03110640
138NCT02685670Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/LymphomaRecruitingNo Results AvailableHematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell LymphomaBiological: anti-CD19 CAR-T|Drug: Fludarabine|Drug: CyclophosphamideThe Second Affiliated Hospital of Henan University of Traditional Chinese Medicine|Xinqiao Hospital of Chongqing|Xuzhou Medical UniversityPhase 1|Phase 220https://ClinicalTrials.gov/show/NCT02685670
139NCT02903810Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic MalignancyRecruitingNo Results AvailableHematopoietic/Lymphoid CancerBiological: Mixed CAR-T TransferXuzhou Medical UniversityPhase 1|Phase 220https://ClinicalTrials.gov/show/NCT02903810
140NCT03338972Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple MyelomaRecruitingNo Results AvailableRecurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|TNFRSF17 PositiveBiological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: LeukapheresisFred Hutchinson Cancer Research Center|Juno Therapeutics, Inc.|National Cancer Institute (NCI)Phase 125https://ClinicalTrials.gov/show/NCT03338972
141NCT02706782A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic CarcinomaRecruitingNo Results AvailablePancreatic CancerDrug: TAI-meso-CARTShanghai GeneChem Co., Ltd.Phase 130https://ClinicalTrials.gov/show/NCT02706782
142NCT02715362A Study of GPC3 Redirected Autologous T Cells for Advanced HCCRecruitingNo Results AvailableCarcinoma, HepatocellularDrug: TAI-GPC3-CART cellsShanghai GeneChem Co., Ltd.Phase 1|Phase 230https://ClinicalTrials.gov/show/NCT02715362
143NCT02794246CART-19 Post-ASCT for Multiple MyelomaActive, not recruitingNo Results AvailableMultiple MyelomaBiological: CART-19 cellsUniversity of PennsylvaniaPhase 225https://ClinicalTrials.gov/show/NCT02794246
144NCT03366324Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell MalignanciesRecruitingNo Results AvailableAcute Lymphoblastic Leukemia|B Cell LymphomaGenetic: Second generation CAR-T cells|Procedure: Hematological stem cell transplantationWuhan Sian Medical Technology Co., Ltd|Wuhan Union Hospital, China|Jingzhou Central Hospital|Xiangyang Central Hospital|People's Hospital Of YichangPhase 120https://ClinicalTrials.gov/show/NCT03366324
145NCT02862704A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)RecruitingNo Results AvailableLiver MetastasesBiological: MG7-CARTXijing Hospital|Shanghai GeneChem Co., Ltd.Phase 1|Phase 220https://ClinicalTrials.gov/show/NCT02862704
146NCT03299738A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHLNot yet recruitingNo Results AvailableRefractory or Relapsed B-cell Non-Hodgkin LymphomaBiological: C-CAR011Cellular Biomedicine Group Ltd.|Tianjin Medical University Cancer Institute and HospitalPhase 110https://ClinicalTrials.gov/show/NCT03299738
147NCT03060343Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)RecruitingNo Results AvailableNon-small Cell Lung CancerBiological: Zeushield Cytotoxic T LymphocytesYu Fenglei|Hunan Zhaotai Yongren Biotech Co. Ltd.|Hunan Yongren Medical Innovation Co. Ltd.|Second Xiangya Hospital of Central South UniversityEarly Phase 110https://ClinicalTrials.gov/show/NCT03060343
148NCT02992210Study on GD2 Positive Solid Tumors by 4SCAR-GD2RecruitingNo Results AvailableSolid TumorGenetic: 4SCAR-GD2Shenzhen Geno-Immune Medical InstitutePhase 1|Phase 2100https://ClinicalTrials.gov/show/NCT02992210
149NCT02924753The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).RecruitingNo Results AvailableB-cell Acute Lymphoblastic LeukemiaDrug: Cyclophosphamide|Drug: Fludarabine|Biological: CART-19 cellsHenan Cancer Hospital|The Beijing Pregene Science and Technology Company, Ltd.Phase 120https://ClinicalTrials.gov/show/NCT02924753
150NCT03013712A Clinical Research of CAR T Cells Targeting EpCAM Positive CancerRecruitingNo Results AvailableColon Cancer|Esophageal Carcinoma|Pancreatic Cancer|Prostate Cancer|Gastric Cancer|Hepatic CarcinomaBiological: CAR-T cell immunotherapyFirst Affiliated Hospital of Chengdu Medical CollegePhase 1|Phase 260https://ClinicalTrials.gov/show/NCT03013712
151NCT03393936Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Metastatic Renal Cell CarcinomaRecruitingNo Results AvailableRenal Cell CarcinomaBiological: CCT301-38|Biological: CCT301-59Shanghai Sinobioway Sunterra BiotechPhase 1|Phase 266https://ClinicalTrials.gov/show/NCT03393936
152NCT02746952Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic LeukaemiaRecruitingNo Results AvailableB-cell Acute Lymphoblastic LeukemiaGenetic: UCART19ServierPhase 140https://ClinicalTrials.gov/show/NCT02746952
153NCT02159495Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecruitingNo Results AvailableAdult Acute Myeloid Leukemia in Remission|Donor|Early Relapse of Acute Myeloid Leukemia|Late Relapse of Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Blastic Plasmacytoid Dendritic Cell NeoplasmDrug: cyclophosphamide|Biological: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Other: laboratory biomarker analysis|Biological: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|Drug: Fludarabine PhosphateCity of Hope Medical Center|National Cancer Institute (NCI)Phase 160https://ClinicalTrials.gov/show/NCT02159495
154NCT02146924Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic LeukemiaRecruitingNo Results AvailableB-cell Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Minimal Residual DiseaseBiological: Chimeric Antigen Receptor T-Cell Therapy|Other: laboratory biomarker analysisCity of Hope Medical Center|National Cancer Institute (NCI)Phase 148https://ClinicalTrials.gov/show/NCT02146924
155NCT03179007CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid TumorRecruitingNo Results AvailableAdvanced Solid TumorBiological: Anti-CTLA-4/PD-1 expressing MUC1-CAR-TShanghai Cell Therapy Research InstitutePhase 1|Phase 240https://ClinicalTrials.gov/show/NCT03179007
156NCT03182816CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid TumorRecruitingNo Results AvailableAdvanced Solid TumorBiological: anti-CTLA-4/PD-1 expressing EGFR-CAR-TShanghai Cell Therapy Research InstitutePhase 1|Phase 240https://ClinicalTrials.gov/show/NCT03182816
157NCT03182803CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid TumorRecruitingNo Results AvailableAdvanced Solid TumorBiological: CTLA-4/PD-1 antibodies expressing mesoCAR-TShanghai Cell Therapy Research InstitutePhase 1|Phase 240https://ClinicalTrials.gov/show/NCT03182803
158NCT02315612Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell MalignanciesRecruitingNo Results AvailableFollicular Lymphoma|ALL|NHL|Large Cell LymphomaBiological: CD22-CARNational Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Phase 1115https://ClinicalTrials.gov/show/NCT02315612
159NCT03155191Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic LeukemiaRecruitingNo Results AvailableLymphoblastic Leukemia, Acute AdultBiological: TBI-1501Takara Bio Inc.Phase 1|Phase 221https://ClinicalTrials.gov/show/NCT03155191
160NCT01818323Phase I Trial: T4 Immunotherapy of Head and Neck CancerRecruitingNo Results AvailableHead and Neck CancerOther: Intra-tumoral T4 immunotherapyKing's College London|Guy's and St Thomas' NHS Foundation TrustPhase 130https://ClinicalTrials.gov/show/NCT01818323
161NCT00889954Her2 and TGFBeta CTLs in Treatment of Her2 Positive MalignancyActive, not recruitingNo Results AvailableHER2 Positive MalignanciesBiological: TGFBeta resistant HER2/EBV-CTLsBaylor College of Medicine|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of MedicinePhase 120https://ClinicalTrials.gov/show/NCT00889954
162NCT02782351Humanized CAR-T Therapy for Treatment of B Cell MalignancyRecruitingNo Results AvailableLeukemia, Lymphocytic, Chronic, B-CellBiological: CAR-TKai Lin Xu; Jun Nian Zheng|iCarTAB BioMed Inc.|Huaian first people's hospital|Xuzhou Medical UniversityPhase 1|Phase 250https://ClinicalTrials.gov/show/NCT02782351
163NCT03271515Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLLNot yet recruitingNo Results AvailableLeukemia|LymphomaBiological: anti-CD19 anti-CD20 Bispecific CAR-TBeijing Doing Biomedical Co., Ltd.Phase 120https://ClinicalTrials.gov/show/NCT03271515
164NCT02963038CAR T Cells for Refractory B Cell MalignancyRecruitingNo Results AvailableB-Cell Leukemia|B-Cell LymphomaBiological: Autologous CD19-targeting CAR T cellsHebei Senlang Biotechnology Inc., Ltd.|The Second Hospital of Hebei Medical UniversityPhase 1|Phase 210https://ClinicalTrials.gov/show/NCT02963038
165NCT03166878A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and LymphomaRecruitingNo Results AvailableB Cell Leukemia|B Cell LymphomaBiological: UCART019Chinese PLA General HospitalPhase 1|Phase 280https://ClinicalTrials.gov/show/NCT03166878
166NCT03084380Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)Not yet recruitingNo Results AvailableHepatocellular CarcinomaBiological: Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|Drug: Fludarabine|Drug: CyclophosphamideXinqiao Hospital of ChongqingPhase 1|Phase 220https://ClinicalTrials.gov/show/NCT03084380
167NCT02028455A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ LeukemiaRecruitingNo Results AvailableCD19+ Acute LeukemiaBiological: Patient Derived CD19 specific CAR T cells also expressing an EGFRtSeattle Children's HospitalPhase 1|Phase 280https://ClinicalTrials.gov/show/NCT02028455
168NCT03068416CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells MalignancyRecruitingNo Results AvailableB-cell Leukemia|B-Cell LymphomaBiological: CAR T cellsUppsala University|Uppsala University Hospital|AFA försäkringarPhase 215https://ClinicalTrials.gov/show/NCT03068416
169NCT03064269CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic LeukemiaRecruitingNo Results AvailableB-cell Acute Lymphocytic LeukemiaBiological: CD19 CAR-T cellsShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|The First Affiliated Hospital of Soochow UniversityPhase 110https://ClinicalTrials.gov/show/NCT03064269
170NCT03142646Safety and Efficacy Evaluation of IM19 CAR-T CellsRecruitingNo Results AvailableLeukemiaBiological: IM19 CAR-TBeijing Immunochina Medical Science & Technology Co., Ltd.Phase 120https://ClinicalTrials.gov/show/NCT03142646
171NCT02958384A Clinical Research of LeY-Targeted CAR-T in Myeloid MalignanciesRecruitingNo Results AvailableMyeloid MalignanciesBiological: Anti-LeY-CAR-transduced T cellsSouthwest Hospital, ChinaPhase 1|Phase 245https://ClinicalTrials.gov/show/NCT02958384
172NCT03101709The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell LymphomaRecruitingNo Results AvailableB Cell LymphomaDrug: Cyclophosphamide|Drug: Fludarabine|Biological: CART-19Henan Cancer Hospital|The Beijing Pregene Science and Technology Company, Ltd.Phase 130https://ClinicalTrials.gov/show/NCT03101709
173NCT02958397A Clinical Research of CD33-Targeted CAR-T in Myeloid MalignanciesRecruitingNo Results AvailableMyeloid MalignanciesBiological: Anti-CD33-CAR-transduced T cellsSouthwest Hospital, ChinaPhase 1|Phase 245https://ClinicalTrials.gov/show/NCT02958397
174NCT02937103A Clinical Research of CD123-Targeted CAR-T in Myeloid MalignanciesRecruitingNo Results AvailableLeukemiaBiological: Anti-CD123-CAR-transduced T cellsSouthwest Hospital, ChinaPhase 1|Phase 245https://ClinicalTrials.gov/show/NCT02937103
175NCT02710149A Clinical Research of CD20-Targeted CAR-T in B Cell MalignanciesRecruitingNo Results AvailableLeukemia|LymphomaBiological: Anti-CD20-CAR-transduced T cellsSouthwest Hospital, ChinaPhase 1|Phase 245https://ClinicalTrials.gov/show/NCT02710149
176NCT02954445A Clinical Research of BCMA-Targeted CAR-T in B Cell MalignanciesRecruitingNo Results AvailableLeukemia|Lymphoma|Multiple MyelomaBiological: Anti-BCMA-CAR-transduced T cellsSouthwest Hospital, ChinaPhase 1|Phase 245https://ClinicalTrials.gov/show/NCT02954445
177NCT02958410A Clinical Research of CD30-Targeted CAR-T in Lymphocyte MalignanciesRecruitingNo Results AvailableLeukemia|LymphomaBiological: Anti-CD30-CAR-transduced T cellsSouthwest Hospital, ChinaPhase 1|Phase 245https://ClinicalTrials.gov/show/NCT02958410
178NCT03152435EGFR CART Cells for Patients With Metastatic Colorectal CancerRecruitingNo Results AvailableEGFR-positive Colorectal CancerBiological: EGFR CARTShenzhen Second People's Hospital|The Beijing Pregene Science and Technology Company, Ltd.Phase 1|Phase 220https://ClinicalTrials.gov/show/NCT03152435
179NCT02935153A Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesRecruitingNo Results AvailableLeukemia|LymphomaBiological: Anti-CD22-CAR-transduced T cellsSouthwest Hospital, ChinaPhase 1|Phase 245https://ClinicalTrials.gov/show/NCT02935153
180NCT03146533CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.RecruitingNo Results AvailableB Cell LymphomaDrug: Fludarabine|Drug: Cyclophosphamide|Biological: CD19 CARTShenzhen Second People's Hospital|The Beijing Pregene Science and Technology Company, Ltd.Phase 1|Phase 220https://ClinicalTrials.gov/show/NCT03146533
181NCT02822326Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute LeukemiaRecruitingNo Results AvailableAcute LeukemiaBiological: CD19-CAR-T2 CellsGuangdong General Hospital|Chinese Academy of Sciences|Guangdong Zhaotai InVivo Biomedicine Company LimitedPhase 130https://ClinicalTrials.gov/show/NCT02822326
182NCT02737085the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)Active, not recruitingNo Results AvailableLymphoma, Large B-Cell, DiffuseBiological: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cellsSouthwest Hospital, ChinaPhase 1|Phase 240https://ClinicalTrials.gov/show/NCT02737085
183NCT02443831CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological MalignanciesRecruitingNo Results AvailableAcute Lymphoblastic Leukemia|Burkitt LymphomaProcedure: Leukapheresis|Drug: Lymphodepletion with fludarabine|Drug: Lymphodepletion with cyclophosphamide|Biological: CD19 CAR T-cellsUniversity College, LondonPhase 118https://ClinicalTrials.gov/show/NCT02443831
184NCT02587689Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid TumorRecruitingNo Results AvailableHepatocellular Carcinoma|Non-small Cell Lung Cancer|Pancreatic Carcinoma|Triple-Negative Invasive Breast CarcinomaBiological: anti-MUC1 CAR T CellsPersonGen BioTherapeutics (Suzhou) Co., Ltd.|The First People's Hospital of Hefei|Hefei Binhu HospitalPhase 1|Phase 220https://ClinicalTrials.gov/show/NCT02587689
185NCT02348216A Phase 1-2 Multi-Center Study Evaluating Axicabtagene Ciloleucel in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)RecruitingNo Results AvailableRefractory Diffuse Large B Cell Lymphoma|Refractory Primary Mediastinal B Cell Lymphoma|Refractory Transformed Follicular Lymphoma|Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma|Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma|Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma|Relapsed/Refractory Large B Cell Lymphoma Including DLBCL, PMBCL, TFL and HGBCL After Two Systemic Lines of Therapy" in Phase 2 Expanded CohortsBiological: axicabtagene ciloleucelKite, A Gilead CompanyPhase 1|Phase 2200https://ClinicalTrials.gov/show/NCT02348216
186NCT02614066A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)RecruitingNo Results AvailableAcute Lymphoblastic LeukemiaBiological: KTE-C19Kite, A Gilead CompanyPhase 1|Phase 275https://ClinicalTrials.gov/show/NCT02614066
187NCT02625480A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaRecruitingNo Results AvailableAcute Lymphoblastic LeukemiaBiological: KTE-C19Kite, A Gilead CompanyPhase 1|Phase 275https://ClinicalTrials.gov/show/NCT02625480
188NCT02968472A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell LeukemiaRecruitingNo Results AvailableB Acute Lymphoblastic LeukemiaGenetic: prophylactic 4SCAR19 cellsThe First People's Hospital of Yunnan|Shenzhen Geno-Immune Medical InstitutePhase 130https://ClinicalTrials.gov/show/NCT02968472
189NCT03121625CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid MalignanciesRecruitingNo Results AvailableLeukemia|LymphomaBiological: Autologous CAR-THebei Senlang Biotechnology Inc., Ltd.|Hebei Medical University Fourth HospitalPhase 130https://ClinicalTrials.gov/show/NCT03121625
190NCT03312205CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid MalignanciesRecruitingNo Results AvailableLeukemia|Lymphoma|Multiple Myeloma of Bone (Diagnosis)Biological: Autologous CAR-T cellsHebei Senlang Biotechnology Inc., Ltd.|Hebei Yanda Ludaopei Hospital|Beijing Ludaopei HospitalPhase 1|Phase 250https://ClinicalTrials.gov/show/NCT03312205
191NCT02794961CD22 Targeting CAR-T Therapy Against B Cell Hematological MalignanciesRecruitingNo Results AvailableRecurrent or Refractory B Cell MalignancyBiological: CD22 CAR-TKai Lin Xu; Jun Nian Zheng|iCarTAB BioMed Inc.|Xuzhou Medical UniversityPhase 1|Phase 210https://ClinicalTrials.gov/show/NCT02794961
192NCT03258047Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell LymphomaRecruitingNo Results AvailableB Cell LymphomaCombination Product: CAR-TFirst Affiliated Hospital of Zhejiang UniversityPhase 260https://ClinicalTrials.gov/show/NCT03258047
193NCT03191773A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell MalignanciesRecruitingNo Results AvailableAcute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|LymphomaCombination Product: Drugs and anti-CD19 CAR transduced T cellsSecond Affiliated Hospital of Guangzhou Medical University|Shenzhen Institute for Innovation and Translational Medicine|Guangzhou First People's Hospital|First People's Hospital of Foshan|Dongguan People's Hospital|The First Affiliated Hospital of Guangdong Pharmaceutical UniversityPhase 1|Phase 2100https://ClinicalTrials.gov/show/NCT03191773
194NCT02926833A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)RecruitingNo Results AvailableRefractory Diffuse Large B Cell LymphomaBiological: KTE-C19|Drug: atezolizumab (anti-PD-L1)Kite, A Gilead Company|Genentech, Inc.Phase 1|Phase 231https://ClinicalTrials.gov/show/NCT02926833
195NCT02624258Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin LymphomaRecruitingNo Results AvailableHodgkin LymphomaBiological: CD19 RNA redirected autologous T-cells (RNA CART19 cells)University of Pennsylvania|Children's Hospital of PhiladelphiaEarly Phase 110https://ClinicalTrials.gov/show/NCT02624258
196NCT02666248Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer StudiesEnrolling by invitationNo Results AvailableSubjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII InfusionUniversity of Pennsylvania8https://ClinicalTrials.gov/show/NCT02666248
197NCT02713984A Clinical Research of CAR T Cells Targeting HER2 Positive CancerRecruitingNo Results AvailableBreast Cancer|Ovarian Cancer|Lung Cancer|Gastric Cancer|Colorectal Cancer|Glioma|Pancreatic CancerBiological: Anti-HER2 CAR-TZhi Yang|Southwest Hospital, ChinaPhase 1|Phase 260https://ClinicalTrials.gov/show/NCT02713984
198NCT02965157Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ LymphomaRecruitingNo Results AvailableLymphoma, B-CellBiological: CART20Beijing Biohealthcare Biotechnology Co.,LtdPhase 1|Phase 215https://ClinicalTrials.gov/show/NCT02965157
199NCT03050190A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell MalignanciesRecruitingNo Results AvailableB-cell MalignanciesGenetic: Therapeutic 4SCAR19 cellsShenzhen Geno-Immune Medical InstitutePhase 1|Phase 2200https://ClinicalTrials.gov/show/NCT03050190
200NCT03125577Combination CAR-T Cell Therapy Targeting Hematological MalignanciesRecruitingNo Results AvailableB-cell MalignanciesBiological: 4SCAR19 and 4SCAR22|Biological: 4SCAR19 and 4SCAR38|Biological: 4SCAR19 and 4SCAR20|Biological: 4SCAR19 and 4SCAR123Shenzhen Geno-Immune Medical InstitutePhase 1|Phase 2100https://ClinicalTrials.gov/show/NCT03125577
201NCT02546167CART-BCMA Cells for Multiple MyelomaActive, not recruitingNo Results AvailableMultiple MyelomaBiological: CART-BCMAUniversity of PennsylvaniaPhase 125https://ClinicalTrials.gov/show/NCT02546167
202NCT02030834Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ LymphomasRecruitingNo Results AvailableNon-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell LymphomasBiological: CART-19University of PennsylvaniaPhase 257https://ClinicalTrials.gov/show/NCT02030834
203NCT03423706Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell TransplantationRecruitingNo Results AvailableCD19-chimeric Antigen Receptor T Cells|Relapsed and/or Refractory Acute Lymphoblastic Leukemia|the Haploidentical Hematopoietic Stem Cell TransplantationProcedure: the new model of haplo-HSCT for r/r B-ALLFirst Affiliated Hospital of Harbin Medical University50https://ClinicalTrials.gov/show/NCT03423706
204NCT02030847Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic LeukemiaActive, not recruitingNo Results AvailablePatients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment OptionsBiological: CART-19University of PennsylvaniaPhase 230https://ClinicalTrials.gov/show/NCT02030847
205NCT03330691A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and LymphomaRecruitingNo Results AvailableLeukemia|LymphomaBiological: Patient-derived CD19- and CD22 specific CARSeattle Children's HospitalPhase 133https://ClinicalTrials.gov/show/NCT03330691
206NCT02721407Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma PatientsRecruitingNo Results AvailableRecurrent Adult Diffuse Large Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Stage III/IV Adult Diffuse Large Cell Lymphoma|Stage III/IV Follicular Lymphoma|Stage III/IV Mantle Cell LymphomaDrug: Retroviral vector-transduced autologous T cells to express CD22-specific CARsXinqiao Hospital of Chongqing|Xuzhou Medical UniversityPhase 120https://ClinicalTrials.gov/show/NCT02721407
207NCT02786511Longterm Follow-up of Subjects Treated With bb2121Enrolling by invitationNo Results AvailableMultiple MyelomaDrug: Safety and efficacy assessmentsCelgene50https://ClinicalTrials.gov/show/NCT02786511
208NCT03208556Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell LymphomaRecruitingNo Results AvailableRelapsed or Refractory B-cell LymphomaBiological: iPD1 CD19 eCAR T cells|Drug: Fludarabine and cyclophosphamidePeking University|Marino Biotechnology Co., Ltd.Phase 120https://ClinicalTrials.gov/show/NCT03208556
209NCT02652910Memory-enriched CAR-T Cells Immunotherapy for B Cell LymphomaRecruitingNo Results AvailableRecurrent Adult Diffuse Large Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Follicular Lymphoma|Stage IV Mantle Cell LymphomaDrug: CD19.CAR-T cellsXinqiao Hospital of Chongqing|Xuzhou Medical UniversityPhase 1|Phase 220https://ClinicalTrials.gov/show/NCT02652910
210NCT02388828CART-meso Long-term Follow-upActive, not recruitingNo Results AvailableSubjects Who Have Received Lentiviral-based CART-meso TherapyBiological: lentiviral-based CART meso therapyUniversity of Pennsylvania50https://ClinicalTrials.gov/show/NCT02388828
211NCT02842320Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)RecruitingNo Results AvailableChronic Myeloid LeukemiaOther: biological samplesCentre Hospitalier Universitaire de Besancon40https://ClinicalTrials.gov/show/NCT02842320
212NCT01722149Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural MesotheliomaRecruitingNo Results AvailableMalignant Pleural MesotheliomaGenetic: Adoptive Transfer of re-directed T cellsUniversity of ZurichPhase 16https://ClinicalTrials.gov/show/NCT01722149
213NCT01626495Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and LymphomaActive, not recruitingNo Results AvailableB Cell Leukemia|B Cell LymphomaBiological: CART-19University of PennsylvaniaPhase 176https://ClinicalTrials.gov/show/NCT01626495
214NCT03226704Leukapheresis for CAR-Therapy ManufacturingRecruitingNo Results AvailableLeukemia|Lymphoma|Acute Lymphoblastic Leukemia|Diffuse Large B-Cell Lymphoma|Non-Hodgkin's LymphomaNational Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)120https://ClinicalTrials.gov/show/NCT03226704
215NCT03321123MB-CART19.1 in Patients With R/R ALLNot yet recruitingNo Results AvailablePrecursor B-Lymphoblastic Lymphoma/Leukaemia RefractoryDrug: MB-CART19.1Shanghai Children's Medical Center|Miltenyi Biotec GmbHPhase 210https://ClinicalTrials.gov/show/NCT03321123
216NCT03016377Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaRecruitingNo Results AvailableAcute Lymphoblastic Leukemia|Immune System Diseases|Immunoproliferative DisordersBiological: iC9-CAR19 cells|Drug: AP1903|Drug: Cyclophosphamide|Drug: FludarabineUNC Lineberger Comprehensive Cancer CenterPhase 140https://ClinicalTrials.gov/show/NCT03016377
217NCT01318317Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin LymphomaActive, not recruitingNo Results AvailableRecurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell LymphomaProcedure: peripheral blood stem cell transplantation (PBSCT)|Biological: filgrastim|Genetic: polymerase chain reaction|Biological: rituximab|Biological: genetically engineered lymphocyte therapy|Other: laboratory biomarker analysis|Drug: plerixafor|Procedure: autologous hematopoietic stem cell transplantationCity of Hope Medical Center|National Cancer Institute (NCI)Phase 1|Phase 257https://ClinicalTrials.gov/show/NCT01318317
218NCT03389035Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCTRecruitingNo Results AvailableAcute Lymphoblastic Leukemia, in RelapseBiological: CARCIK-CD19Fondazione Matilde Tettamanti Menotti De Marchi OnlusPhase 1|Phase 218https://ClinicalTrials.gov/show/NCT03389035
219NCT03274219Study of bb21217 in Multiple MyelomaRecruitingNo Results AvailableMultiple MyelomaBiological: bb21217bluebird bioPhase 150https://ClinicalTrials.gov/show/NCT03274219
220NCT03289455CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALLRecruitingNo Results AvailableB Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia|B-cell Acute Lymphoblastic LeukemiaBiological: AUTO3 (CD19/22 CAR T cellsAutolus LimitedPhase 1|Phase 250https://ClinicalTrials.gov/show/NCT03289455
221NCT03287817CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell LymphomaRecruitingNo Results AvailableDiffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|DLBCLBiological: AUTO3Autolus LimitedPhase 1|Phase 2120https://ClinicalTrials.gov/show/NCT03287817
222NCT02658929Study of bb2121 in Multiple MyelomaRecruitingNo Results AvailableMultiple MyelomaBiological: bb2121Celgene|bluebird bioPhase 150https://ClinicalTrials.gov/show/NCT02658929
223NCT02813252Long-Term Follow-up Study for Patients Previously Treated With JCAR015Enrolling by invitationNo Results AvailableAcute Lymphoblastic LeukemiaGenetic: JCAR015Juno Therapeutics, Inc.500https://ClinicalTrials.gov/show/NCT02813252
224NCT03288493P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)RecruitingNo Results AvailableMultiple MyelomaBiological: P-BCMA-101 CAR-T cellsPoseida Therapeutics, Inc.Phase 140https://ClinicalTrials.gov/show/NCT03288493
225NCT01430390In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell MalignanciesRecruitingNo Results AvailableAcute Lymphocytic Leukemia|LymphomaBiological: Biological/Genetically Modified T cellsMemorial Sloan Kettering Cancer CenterPhase 112https://ClinicalTrials.gov/show/NCT01430390
226NCT03436771Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductEnrolling by invitationNo Results AvailableNon Hodgkin Lymphoma|Multiple Myeloma|Chronic Lymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Mantle Cell Lymphoma|Follicular LymphomaGenetic: JCAR017|Genetic: JCARH125Juno Therapeutics, Inc.600https://ClinicalTrials.gov/show/NCT03436771
227NCT01860937T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic LeukemiaActive, not recruitingNo Results AvailableRelapsed B-Cell Acute Lymphoblastic LeukemiaProcedure: leukapheresis or collection of PBMCs|Drug: cyclophosphamide based chemotherapy regimens|Biological: modified T cellsMemorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute:Dana- Farber/Children's HospitalPhase 123https://ClinicalTrials.gov/show/NCT01860937
228NCT03389230Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV GliomaNot yet recruitingNo Results AvailableGlioblastoma|HER2/Neu Positive|Malignant Glioma|Recurrent Glioma|WHO Grade III/IV GliomaProcedure: Leukapheresis|Biological: HER2(EQ)BBζ/CD19t+ Tcm|Other: Laboratory Biomarker AnalysisCity of Hope Medical Center|Mustang Bio, Inc.Phase 181https://ClinicalTrials.gov/show/NCT03389230
229NCT02917083CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)RecruitingNo Results AvailableHodgkin's Lymphoma|Non-Hodgkin LymphomaGenetic: CAR T Cells|Drug: Cyclophosphamide|Drug: FludarabineBaylor College of Medicine|The Methodist Hospital System|Texas Children's HospitalPhase 118https://ClinicalTrials.gov/show/NCT02917083
230NCT03271632Multi-CAR T Cell Therapy in the Treatment of Multiple MyelomaRecruitingNo Results AvailableMultiple MyelomaBiological: CAR T cellsShenzhen Geno-Immune Medical InstitutePhase 1|Phase 220https://ClinicalTrials.gov/show/NCT03271632
231NCT03310619A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)RecruitingNo Results AvailableLymphoma, Non-Hodgkin|Lymphoma, Large B-Cell, Diffuse|Lymphoma, FollicularBiological: JCAR017|Drug: DurvalumabCelgene|Juno Therapeutics, Inc.Phase 1|Phase 250https://ClinicalTrials.gov/show/NCT03310619
232NCT03331198Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory CLL or SLL (TRANSCEND-CLL-004)RecruitingNo Results AvailableLeukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, Small LymphocyticBiological: JCAR017 (lisocabtagene maraleucel)|Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib|Drug: Standard of careJuno Therapeutics, Inc.Phase 1|Phase 2205https://ClinicalTrials.gov/show/NCT03331198
233NCT02445248Study of Efficacy and Safety of CTL019 in Adult DLBCL PatientsRecruitingNo Results AvailableDiffuse Large B-cell Lymphoma (DLBCL)Biological: CTL019Novartis Pharmaceuticals|NovartisPhase 2130https://ClinicalTrials.gov/show/NCT02445248
234NCT02580747Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-mesoRecruitingNo Results AvailableMalignant Mesothelioma|Pancreatic Cancer|Ovarian Tumor|Triple Negative Breast Cancer|Endometrial Cancer|Other Mesothelin Positive TumorsBiological: anti-meso-CAR vector transduced T cellsChinese PLA General HospitalPhase 120https://ClinicalTrials.gov/show/NCT02580747
235NCT02541370Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133RecruitingNo Results AvailableLiver Cancer|Pancreatic Cancer|Brain Tumor|Breast Cancer|Ovarian Tumor|Colorectal Cancer|Acute Myeloid and Lymphoid LeukemiasBiological: anti-CD133-CAR vector-transduced T cellsChinese PLA General HospitalPhase 120https://ClinicalTrials.gov/show/NCT02541370